Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | LTA4H | P09960 | 14/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.56 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 3/20 | 0.53 |
| ▸ | PPARA | Q07869 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4688863 | 0.86 | LTA4H (0.62) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL4688901 | 0.83 | CYP1A2 (0.63) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL11471037 | 0.82 | CYP1A2 (0.73) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL17057706 | 0.82 | CSNK1D (0.48) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL18580730 | 0.82 | EPHX2 (0.58) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL4692258 | 0.82 | CYP1A2 (0.59) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL3491330 | 0.82 | CYP1A2 (1.00) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL357361 | 0.81 | SMN1; SMN2 (0.71) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL4689887 | 0.81 | CYP1A2 (0.60) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL4688967 | 0.81 | LTA4H (0.64) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | SMN1; SMN2 4779/4885CYP1A2 3046/4885CYP3A4 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.